Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H15N3O3 |
| Molecular Weight | 249.2658 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCOC1=CC2=C(NC(NC(=O)OC)=N2)C=C1
InChI
InChIKey=RAOCRURYZCVHMG-UHFFFAOYSA-N
InChI=1S/C12H15N3O3/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
| Molecular Formula | C12H15N3O3 |
| Molecular Weight | 249.2658 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.drugbank.ca/drugs/DB04910
Sources: https://www.drugbank.ca/drugs/DB04910
Oxibendazole is an anthelmintics drug which is used to protect against roundworms, strongyles, threadworms, pinworms and lungworm infestations in horses and other domestic pets. Oxibendazole causes degenerative alterations in the tegument and intestinal cells of the worm by binding to the colchicine-sensitive site of tubulin, thus inhibiting its polymerization or assembly into microtubules.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P50719 Gene ID: NA Gene Symbol: NA Target Organism: Haemonchus contortus (Barber pole worm) Sources: https://www.ncbi.nlm.nih.gov/pubmed/3755220 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Anthelcide EQ Approved UseAnthelcide EQ Paste is indicated for removal and control of: large strongyles (Strongylus edentatus, S. equinus, S. vulgaris); small strongyles (species of the genera Cylicostephanus, Cylicocyclus, Cyathostomum, Triodontophorus, Cylicodontophorus, and Gyalocephalus); large roundworms (Parascaris equorum); pinworms (Oxyuris equi) including various larval stages; and threadworms (Strongyloides westeri). |
PubMed
| Title | Date | PubMed |
|---|---|---|
| FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1. | 2013-09-05 |
|
| Further evaluation in field tests of the activity of three anthelmintics (fenbendazole, oxibendazole, and pyrantel pamoate) against the ascarid Parascaris equorum in horse foals on eight farms in Central Kentucky (2009-2010). | 2011-10 |
|
| Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway. | 2011-03 |
|
| Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes. | 2010-02-03 |
|
| Diagnosis and control of anthelmintic-resistant Parascaris equorum. | 2009-09-25 |
|
| Restrictions of anthelmintic usage: perspectives and potential consequences. | 2009-09-25 |
|
| Determination of genomic DNA sequences for beta-tubulin isotype 1 from multiple species of cyathostomin and detection of resistance alleles in third-stage larvae from horses with naturally acquired infections. | 2009-09-25 |
|
| Anthelmintic resistance in cyathostomin populations from horse yards in Italy, United Kingdom and Germany. | 2009-09-25 |
|
| Equine cyathostomins: a review of biology, clinical significance and therapy. | 2009-09-25 |
|
| Species-specific identification of equine cyathostomes resistant to fenbendazole and susceptible to oxibendazole and moxidectin by macroarray probing. | 2009-01 |
|
| The little-known scenario of anthelmintic resistance in equine cyathostomes in Italy. | 2008-12 |
|
| Evaluation of parasiticidal activity of fenbendazole, ivermectin, oxibendazole, and pyrantel pamoate in horse foals with emphasis on ascarids (Parascaris equorum) in field studies on five farms in Central Kentucky in 2007. | 2008-07 |
|
| Field studies indicating reduced activity of ivermectin on small strongyles in horses on a farm in Central Kentucky. | 2008-06 |
|
| Study (1991 to 2001) of drug-resistant Population B small strongyles in critical tests in horses in Kentucky at the termination of a 40-year investigation. | 2007-08 |
|
| Parasite field study in central Kentucky on thoroughbred foals (born in 2004) treated with pyrantel tartrate daily and other parasiticides periodically. | 2007-02 |
|
| Field studies on endoparasites of Thoroughbred foals on seven farms in central Kentucky in 2004. | 2006-04 |
|
| Comparative study of sample preparation methods; supported liquid membrane and solid phase extraction in the determination of benzimidazole anthelmintics in biological matrices by liquid chromatography-electrospray-mass spectrometry. | 2006-03-15 |
|
| Prevalence of anthelmintic resistant cyathostomes on horse farms. | 2004-09-15 |
|
| Evaluation of a larval development assay (DrenchRite) for the detection of anthelmintic resistance in cyathostomin nematodes of horses. | 2004-05-07 |
|
| Quantitative chromatographic determination of several benzimidazole anthelmintic molecules in parasite material. | 2003-12-05 |
|
| Population-S benzimidazole- and tetrahydropyrimidine-resistant small strongyles in a pony herd in Kentucky (1977-1999): effects of anthelmintic treatment on the parasites as determined in critical tests. | 2003-11 |
|
| Transtegumental diffusion of benzimidazole anthelmintics into Moniezia benedeni: correlation with their octanol-water partition coefficients. | 2003-06-18 |
|
| An introductory survey of helminth control practices in south africa and anthelmintic resistance on Thoroughbred stud farms in the Western Cape Province. | 2002-12 |
|
| Development and validation of a liquid chromatographic-electrospray tandem mass spectrometric multiresidue method for anthelmintics in milk. | 2002-11-08 |
|
| HPLC assay for albendazole and metabolites in human plasma for clinical pharmacokinetic studies. | 2002-10-15 |
|
| One season of pasture exposure fails to induce a protective resistance to cyathostomes but increases numbers of hypobiotic third-stage larvae. | 2002-08 |
|
| Evaluation of tests for anthelmintic resistance in cyathostomes. | 2002-07-02 |
|
| Plasma disposition, faecal excretion and in vitro metabolism of oxibendazole following oral administration in horses. | 2002-02 |
|
| Continuance of studies on Population S benzimidazole-resistant small strongyles in a Shetland pony herd in Kentucky: effect of pyrantel pamoate (1992-1999). | 2001-01-20 |
|
| Ultrastructural changes in Ascaris suum after oxibendazole treatment. | 1998-02 |
|
| In vitro susceptibilities of the AIDS-associated microsporidian Encephalitozoon intestinalis to albendazole, its sulfoxide metabolite, and 12 additional benzimidazole derivatives. | 1997-12 |
|
| Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice. | 1995-10 |
|
| Susceptibility of Encephalitozoon cuniculi to several drugs in vitro. | 1995-06 |
|
| In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles. | 1994-02 |
Patents
Sample Use Guides
Oxibendazole should be administered orally. The dose depends on species, and constitutes 10-20 mg/kg for dogs, 10-50 mg/kg for cats, 5-15 mg/kg for cattle. 10-15 mg/kg for horses.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3755220
To study binding of oxibendazole to H. contortus tubulin, 10 [3H]oxibendazole (OBZ) was used as a radioligand. Solution was incubated for 15 min at 37°C. Binding was terminated by the addition of a charcoal solution. After 5 min incubation to adsorb unbound drug, the charcoal was sedimented by 5 min centrifugation, and bound [3H]OBZ was counted.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:05:18 GMT 2025
by
admin
on
Mon Mar 31 18:05:18 GMT 2025
|
| Record UNII |
022N12KJ0X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 520.1638
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
||
|
CFR |
21 CFR 520.623
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
||
|
WHO-VATC |
QP52AC57
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
||
|
NCI_THESAURUS |
C250
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
||
|
WHO-VATC |
QP52AC07
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
20559-55-1
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
SUB09521MIG
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
C011321
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
4622
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
022N12KJ0X
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
3437
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
m8305
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | Merck Index | ||
|
022N12KJ0X
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
100000083040
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
OXIBENDAZOLE
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
CHEMBL1087630
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
C66262
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
DTXSID5045625
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
1009342
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | RxNorm | ||
|
DB04910
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
243-877-7
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY | |||
|
758459
Created by
admin on Mon Mar 31 18:05:18 GMT 2025 , Edited by admin on Mon Mar 31 18:05:18 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |